American Society of Clinical Oncology

2064 articles with American Society of Clinical Oncology

• Fusion Pharmaceuticals Announces Poster Presentation at ASCO 2019

  5/16/2019

  Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced that it will present a poster at the 2019 American Society of Clinical Oncology meeting, which is being held from May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois.

• Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings

  5/16/2019

  Epizyme, Inc. announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June.

• Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO

  5/16/2019

  Alligator Bioscience, announces that Janssen Biotech, Inc. will present data from a Phase I clinical study of ADC-1013 at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4.

• Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

  5/16/2019

  Novartis will present data from across its oncology portfolio at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology, taking place May 31-June 4 in Chicago; and the 24th Annual Congress of the European Hematology Association, scheduled for June 13-16 in Amsterdam.

• H3 Biomedicine to Present Data from Two Ongoing Precision Medicine Clinical Programs at 2019 ASCO Annual Meeting

  5/16/2019

  H3 Biomedicine Inc., a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., announced it will present four posters during the 2019 American Society of Clinical Oncology Annual Meeting, which will be held May 31 – June 4, 2019 in Chicago.

• Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

  5/16/2019

  Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials

• AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting

  5/16/2019

  AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA® and IMFINZI® at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 to June 4, 2019.

• Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

  5/16/2019

  New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months

• RemeGen Ltd. Highlights New Data to Be Presented at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/16/2019

  New Data in Bladder Cancer Demonstrates Potential of Clinical Program for HER2 Cancers

• Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

  5/16/2019

  Oncopeptides AB announced that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma have been selected for poster presentation at the 2019 American Society of Clinical Oncology Annual Meeting taking place May 31 – June 4 in Chicago.

• Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

  5/16/2019

  Medicenna Therapeutics Corp. announced that Dr. Dina Randazzo of Duke University, will present updates related to the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 31 to June 4, 2019 in Chicago, Illinois.

• Innovent Will Provide Key Results Update of Several Clinical Studies at 2019 ASCO Annual Meeting

  5/16/2019

  Oral presentation on the results of sintilimab for relapsed/refractory extranodal NK/T cell lymphoma

• IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer

  5/16/2019

  Company to host conference call following ASCO presentation on June 2 to discuss updated clinical data

• Cutting Edge Research from Integra Connect Will be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

  5/16/2019

  Leading Provider of Value-based Specialty Care Solutions Selected to Present Research Assessing the Impact of Oncological Treatment Decisions, Care Management Programs on Clinical Outcomes

• ALX Oncology to Present ALX148 Clinical Data at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/16/2019

  ALX Oncology announced that ALX148 clinical results have been selected for presentation in the Poster Discussion Session at the 2019 ASCO Annual Meeting, May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.

• Merck KGaA, Darmstadt, Germany Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care

  5/15/2019

  Merck KGaA, Darmstadt, Germany announced that data across several modalities and mechanisms targeting difficult-to-treat cancers will be presented at the 2019 American Society of Clinical Oncology Annual Meeting, May 31–June 4, Chicago, IL, US.

• Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting

  5/15/2019

  Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors

• BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

  5/15/2019

  BerGenBio ASA notes the publication of abstracts relating to new interim clinical and biomarker data that the company and its collaborators will present from its extensive Phase II clinical development programme with bemcentinib at the 2019 annual meeting of the American Society of Clinical Oncology at McCormick Place in Chicago, Illinois.

• Rakuten Medical Highlights Upcoming Presentations and Activities During the ASCO Annual Meeting, May 31 - June 4, 2019 in Chicago

  5/15/2019

  Rakuten Medical, a clinical-stage biotechnology company developing precision-targeted cancer therapies based on its proprietary photoimmunotherapy platform, will be presenting data from its Phase 2a clinical trial focused on RM-1929 PIT in patients with locoregional, recurrent head and neck squamous cell carcinoma during the ASCO annual meeting, May 31 – June 4, 2019 in Chicago.

• Janssen to Present Data from Robust Oncology Portfolio and Pipeline at the 2019 ASCO Annual Meeting, Including Best of ASCO Selections

  5/15/2019

  The Janssen Pharmaceutical Companies of Johnson & Johnson announced the latest research from its robust oncology portfolio and pipeline to be presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago from May 31 to June 4.